One Drug.

Many Viruses. Many People.

Introducing D-MAVs^TM,
Designable Multi-Antivirals.

For decades, antivirals have been developed for one virus at a time, always a step behind the next threat. Decoy designs therapeutics that target the machinery many viruses share, so a single, adaptable drug can work across many of them, delivered the way each one demands, before exposure or after.

Built for the viruses we fight every year, and ready for the ones we have not met yet.

Explore D-MAVs

More than 250 human-infecting viruses use the entry machinery we target. We use one platform, have many programs, and are working to advance two of them toward the clinic within 24 months.

Supported by leaders in science, tech and global health:

The Science Behind the Category

IMP³ACT^TM is Decoy’s peptide conjugate platform, engineered to target the mechanisms viruses share rather than what makes each one different. Programs build on a common architecture and adapt quickly, instead of starting over each time.

Learn About the IMP³ACT Platform